OPYL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.023 AUD | -4.17% |
|
-11.54% | -17.86% |
| 06-06 | Opyl Secures First TrialGen Contract with Brain Vector | MT |
| 04-29 | Opyl Expands TrialKey Coverage; Shares Up 38% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 902K 602K 47.32M | Sales 2023 | 618K 412K 32.4M | Capitalization | 1.76M 1.17M 92.25M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.33M -105M | Net income 2023 | -1M -667K -52.44M | EV / Sales 2022 | 1.96 x |
| Net cash position 2022 | 786K 524K 41.24M | Net cash position 2023 | 153K 102K 8.02M | EV / Sales 2023 | 2.6 x |
| P/E ratio 2022 |
-1.23
x | P/E ratio 2023 |
-1.02
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.66% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.17% | ||
| 1 week | -11.54% | ||
| Current month | +4.55% | ||
| 1 month | +27.78% | ||
| 3 months | +4.55% | ||
| 6 months | -34.29% | ||
| Current year | -17.86% |
1 week
0.02
0.03
1 month
0.020.03
Current year
0.020.04
1 year
0.020.06
3 years
0.020.23
5 years
0.020.34
10 years
0.025.70
| Managers | Title | Age | Since |
|---|---|---|---|
Saurabh Jain
CEO | Chief Executive Officer | - | 11-23 |
Marc Angelone
FOU | Founder | - | 16/01/94 |
Damon Rasheed
CTO | Chief Tech/Sci/R&D Officer | - | 29/01/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Simari
BRD | Director/Board Member | 54 | 03/09/23 |
Antanas Guoga
BRD | Director/Board Member | 50 | 03/09/23 |
Marc Angelone
FOU | Founder | - | 16/01/94 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/24 | 0.023 | -4.17% | 370 741 |
| 18/06/24 | 0.024 | 0.00% | 211,401 |
| 17/06/24 | 0.024 | -7.69% | 517,611 |
| 14/06/24 | 0.026 | -13.33% | 212,471 |
| 13/06/24 | 0.03 | +7.14% | 610,181 |
Delayed Quote Australian S.E., June 19, 2024 at 05:50 am
More quotes
Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.
Calendar
26/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.86% | 2.72M | |
| -7.16% | 28.89B | |
| +41.90% | 9.26B | |
| +34.47% | 4.58B | |
| -33.18% | 2.53B | |
| -8.48% | 1.62B | |
| -27.03% | 1.26B | |
| -41.51% | 1.02B | |
| +5.50% | 943M | |
| -41.07% | 845M |
- Stock Market
- Equities
- OPL Stock
